NVSClinical Trials•globenewswire•
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Sentiment:Positive (70)
Summary
Ad hoc announcement pursuant to Art. 53 LR
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 11, 2025 by globenewswire